Dimensional Fund Advisors LP Raises Position in Waters Corporation $WAT

Dimensional Fund Advisors LP raised its position in Waters Corporation (NYSE:WAT) by 3.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 537,582 shares of the medical instruments supplier’s stock after buying an additional 15,762 shares during the period. Dimensional Fund Advisors LP’s holdings in Waters were worth $161,108,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Integrated Wealth Concepts LLC raised its holdings in shares of Waters by 2.9% during the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Waters by 5.9% in the third quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock worth $189,000 after acquiring an additional 35 shares during the last quarter. Penserra Capital Management LLC increased its position in shares of Waters by 13.1% during the second quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 38 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in Waters by 1.8% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock valued at $679,000 after purchasing an additional 41 shares during the last quarter. Finally, Clearstead Advisors LLC raised its stake in Waters by 7.5% in the 3rd quarter. Clearstead Advisors LLC now owns 586 shares of the medical instruments supplier’s stock valued at $176,000 after purchasing an additional 41 shares during the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Waters Stock Performance

NYSE WAT opened at $306.09 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.27 and a current ratio of 1.73. The stock’s fifty day moving average is $359.85 and its two-hundred day moving average is $351.76. The firm has a market capitalization of $30.03 billion, a P/E ratio of 28.42, a price-to-earnings-growth ratio of 2.08 and a beta of 1.20. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15.

Waters (NYSE:WAT) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.50 by $0.03. Waters had a return on equity of 34.79% and a net margin of 20.30%.The business had revenue of $932.36 million during the quarter, compared to the consensus estimate of $928.17 million. During the same period last year, the company earned $4.10 EPS. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. On average, research analysts anticipate that Waters Corporation will post 12.86 earnings per share for the current year.

Analyst Ratings Changes

WAT has been the topic of several recent research reports. Citigroup started coverage on shares of Waters in a research note on Tuesday, February 10th. They set a “buy” rating and a $425.00 target price on the stock. William Blair initiated coverage on shares of Waters in a research report on Monday, January 5th. They issued an “outperform” rating for the company. Robert W. Baird set a $363.00 price target on shares of Waters in a research note on Tuesday, February 10th. UBS Group lowered their price target on shares of Waters from $395.00 to $370.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Finally, Wells Fargo & Company cut their price objective on shares of Waters from $415.00 to $355.00 and set an “equal weight” rating for the company in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $393.84.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.